Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in New York: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 3 | 492 | 46% |
| 2020 | 3 | 475 | 48% |
| 2021 | 2 | 523 | 51% |
| 2022 | 3 | 539 | 53% |
| 2023 | 2 | 491 | 55% |
| 2024 | 3 | 512 | 57% |
| 2025 from claims | – | 534 432–627 | 58% |
| 2026 forecast | – | 549 430–689 | 58% |
| 2027 forecast | – | 562 416–742 | 59% |
| 2028 forecast | – | 575 407–793 | 59% |
| 2029 forecast | – | 588 400–843 | 60% |
| 2030 forecast | – | 601 394–892 | 60% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in New York; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 10% inpatient hospital, 90% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Massachusetts | 4 | 431−1.7%/yr | −1.7%/yr | 0.5 | 0% | 590 in 2030+5.3%/yr |
| Pennsylvania | 3 | 418+0.9%/yr | +0.9%/yr | 0.3 | 0% | 330 in 2030−3.7%/yr |
| New Jersey | 0 | 107−1.1%/yr | −1.1%/yr | 0.1 | 0% | 120 in 2030+1.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 288 | 16,847+0.4%/yr | +0.4%/yr | 9.91.3× | 43% | 18,000 in 2030+1.1%/yr |
| Tumor & fibroid embolization | 22 | 1,661+10%/yr | +10%/yr | 0.91.9× | 48% | 3,360 in 2030+12%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in New York · Every state · Compare with Massachusetts
Exact Sciences leads with 39% of company spending on these surgeons in 2025, +5 pts on 2024.
In 2025, 19 companies reported engagement with New York’s surgeons worth $782K in consulting, speaking, meals and travel tied to these products, about $261K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.